Amneal Pharmaceuticals Of New York, LLC

Amneal Pharmaceuticals Of New York, LLC, a for-profit limited liability company based in Medford, New York, manufactures and supplies specialized pharmaceutical products to federal agencies as a prime contractor, competing exclusively in full-and-open federal markets without set-aside designations. The company's federal footprint centers on narcolepsy medications, nerve agent pretreatment alternatives, and related pharmaceutical solutions delivered through GSA Schedules, Blanket Purchase Agreements, and Other Transaction agreements with the Department of Veterans Affairs, the National Acquisition Center, and the Department of Defense.

Customer concentration at Amneal is extreme and tilted heavily toward a single Veterans Affairs component. The Department of Veterans Affairs Veterans Integrated Service Network 12 accounts for 71 awards totaling $136.6 million in combined potential value — representing 60% of the combined potential value across all 118 prime awards in the source. The National Acquisition Center (a civilian federal procurement entity) follows with 37 awards worth $45.1 million. Together, these two customers represent 92 awards and 86% of Amneal's combined potential value. The remaining federal customer base — Veterans Integrated Service Network 20, the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, HHS's Office of the Assistant Secretary for Administration, and the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense — accounts for seven awards worth roughly $6.1 million combined. Awards are concentrated in pharmaceutical manufacturing (115 of 118 awards) under PSC Drugs and Biologicals (117 awards).

Amneal's vehicle position rests on the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which anchors 153 task orders worth $55.6 million in combined potential value. The company holds four single-award Blanket Purchase Agreements: a $7.5 million BPA for Brekiya awarded by the National Acquisition Center in April 2026, a $2.5 million BPA for sodium oxybate from the National Acquisition Center (ultimate completion December 2025), a $1.71 million Federal Supply Schedule contract with Veterans Integrated Service Network 12, and a $3.82 million Other Transaction IDV with the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense issued in September 2021 for development of alternatives to nerve agent pretreatment medications. Recent named work includes a February 2026 purchase order to supply 1,000 units of Pyridostigmine Bromide to the Defense Logistics Agency's Medical Supply Chain for $148,770, a November 2025 delivery order from VA Veterans Integrated Service Network 20 for Xyrem (sodium oxybate) valued at $319,399 through October 2026, and November 2024 and November 2023 delivery orders from the same VA component worth $173,089 and $185,400 respectively.

Activity has been sparse in recent years — one or two awards annually from 2022 through 2026 — with only one award facing ultimate completion inside the next twenty-four months ($319 thousand combined potential value). The source reflects 118 total awards since 2004, with $22.3 million in combined dollars obligated against a $218.3 million combined potential value, indicating 10% utilization. Amneal has zero sub-award exposure; all 118 awards are prime positions. The company operates as a pure-play pharmaceutical supplier to the federal government with no subcontracting footprint visible in the source data.